Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. It is also developing antibody-drug conjugates for multidrug-resistant bacterial infections that directly kill pathogens and also direct a patient's immune system to attack and eliminate bacterial, fungal, or viral pathogens. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone858-752-6170
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees61
Next Earnings Date2/26/2019 (Estimated)
OptionableOptionable
Cidara Therapeutics (NASDAQ:CDTX) Frequently Asked Questions
What is Cidara Therapeutics' stock symbol?
Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."
How were Cidara Therapeutics' earnings last quarter?
Cidara Therapeutics Inc (NASDAQ:CDTX) posted its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.60) by $0.11. View Cidara Therapeutics' Earnings History.
When is Cidara Therapeutics' next earnings date?
What price target have analysts set for CDTX?
4 equities research analysts have issued twelve-month price targets for Cidara Therapeutics' shares. Their forecasts range from $8.00 to $15.00. On average, they anticipate Cidara Therapeutics' share price to reach $12.3333 in the next twelve months. This suggests a possible upside of 348.5% from the stock's current price. View Analyst Price Targets for Cidara Therapeutics.
What is the consensus analysts' recommendation for Cidara Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cidara Therapeutics.
What are Wall Street analysts saying about Cidara Therapeutics stock?
Here are some recent quotes from research analysts about Cidara Therapeutics stock:
- 1. According to Zacks Investment Research, "Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. " (2/11/2019)
- 2. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution, we reiterate our OW rating and 12-month PT of $15. We think the Street underappreciates the sales potential of CDTX’s two pipeline assets: 1) Rezafungin for the treatment of life-threatening invasive fungal infections, and 2) Cloudbreak, an antimicrobial immunotherapy for the treatment of MDR gram-negative bacterial infections. Therefore, we expect pipeline advancements to drive upward earnings revisions to levels not yet reflected in consensus expectations. This should move CDTX’s stock higher." (8/8/2018)
Has Cidara Therapeutics been receiving favorable news coverage?
Media stories about CDTX stock have been trending somewhat positive on Saturday, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cidara Therapeutics earned a news impact score of 0.8 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
Who are some of Cidara Therapeutics' key competitors?
Some companies that are related to Cidara Therapeutics include Eiger Biopharmaceuticals (EIGR), Sutro Biopharma (STRO), Adverum Biotechnologies (ADVM), LogicBio Therapeutics (LOGC), ADMA Biologics (ADMA), Compugen (CGEN), La Jolla Pharmaceutical (LJPC), Erytech Pharma (ERYP), Jounce Therapeutics (JNCE), Fennec Pharmaceuticals (FENC), Allena Pharmaceuticals (ALNA), Organovo (ONVO), Neon Therapeutics (NTGN), Surface Oncology (SURF) and Pluristem Therapeutics (PSTI).
What other stocks do shareholders of Cidara Therapeutics own?
Who are Cidara Therapeutics' key executives?
Cidara Therapeutics' management team includes the folowing people:
- Dr. Jeffrey L. Stein, Pres, CEO & Exec. Director (Age 64)
- Dr. Taylor Sandison, Chief Medical Officer (Age 47)
- Dr. Kevin M. Forrest Ph.D., Founder and Chief Strategy Officer (Age 42)
- Mr. James E. Levine, Chief Financial Officer (Age 48)
- Mr. Paul Daruwala, COO & Chief Commercial Officer (Age 50)
When did Cidara Therapeutics IPO?
(CDTX) raised $60 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.
Who are Cidara Therapeutics' major shareholders?
Cidara Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Alethea Capital Management LLC (1.74%), Raymond James & Associates (1.19%), BlackRock Inc. (1.05%), Raymond James Financial Services Advisors Inc. (0.97%), Prosight Management LP (0.89%) and Millennium Management LLC (0.76%). Company insiders that own Cidara Therapeutics stock include Jeffrey Stein, Kevin Forrest, Target N V Biotech and Taylor Sandison. View Institutional Ownership Trends for Cidara Therapeutics.
Which institutional investors are selling Cidara Therapeutics stock?
Which institutional investors are buying Cidara Therapeutics stock?
CDTX stock was acquired by a variety of institutional investors in the last quarter, including Raymond James & Associates, Raymond James Financial Services Advisors Inc., Trellus Management Company LLC, Alethea Capital Management LLC, Two Sigma Investments LP and BlackRock Inc.. Company insiders that have bought Cidara Therapeutics stock in the last two years include Jeffrey Stein, Kevin Forrest, Target N V Biotech and Taylor Sandison. View Insider Buying and Selling for Cidara Therapeutics.
How do I buy shares of Cidara Therapeutics?
Shares of CDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cidara Therapeutics' stock price today?
One share of CDTX stock can currently be purchased for approximately $2.75.
How big of a company is Cidara Therapeutics?
Cidara Therapeutics has a market capitalization of $76.31 million. The biotechnology company earns $-55,720,000.00 in net income (profit) each year or ($3.18) on an earnings per share basis. Cidara Therapeutics employs 61 workers across the globe.
What is Cidara Therapeutics' official website?
How can I contact Cidara Therapeutics?
Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-752-6170 or via email at [email protected]
MarketBeat Community Rating for Cidara Therapeutics (NASDAQ CDTX)
MarketBeat's community ratings are surveys of what our community members think about Cidara Therapeutics and other stocks. Vote "Outperform" if you believe CDTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
